key: cord-0683851-zqei8wha
authors: Trémolières, François
title: Antivirals in the time of Covid-19 – not as easy as it looks!
date: 2020-10-15
journal: Med Mal Infect
DOI: 10.1016/j.medmal.2020.10.010
sha: cf5aa52bf7f810a9dbd883d00f0479a8d61db0cb
doc_id: 683851
cord_uid: zqei8wha

nan

Since the onset of this epidemic, one single question has been on everybody's mind:

When will we have an antiviral treatment?

Ten months later, do we have an antiviral treatment yet? NO!

We have only begun to zero in on some medical treatments for symptoms, and that is already no small feat. The one that stands out at the moment is dexamethasone; its use was just validated by the EMA on September 18 [Dexamethasone can be considered a treatment option for adults and adolescents with SARS-CoV-2 infection who require supplemental oxygen therapy]; as well as anticoagulants. Anesthesiologists have only begun, and this is already no small feat, to define progressive optimization of patient care for the most severe cases, and have made significant progress.

How is it possible that our most cautious society had not anticipated the "next up and coming epidemic"?

Antivirals are among the various therapeutic strategies proposed to deal with Covid-19. Research has been conducted since the beginning of 2020 on dozens of known molecules. The perspective of a new Covid-19 specific antiviral treatment seems as distant as ever, considering that the process of perfecting an antivirus is long and laborious as opposed to antibiotics. It must be stated that best practice of clinical tests in the present climate of media panic is difficult [1] .

Even the least educated members of the public know that antibiotics have radically changed the prognostics of bacterial illnesses over the past 80 years. If difficulties are showing up or reappearing today, it is due to the emergence of bacterial resistance created by bacteriae's own defense systems, the proximity of certain illnesses andvery oftenantibiotic misuse. Antibiotic development has been frenetic, and 40 years after the discovery of penicillin, most molecules had already been invented, were known and were efficient and profitable. The end of infectious diseases was even declared by some researchers! This was, of course, not the case at all. Over the next 40 years, from 1980 to 2020, a dozen new bacteriae, and even more new emerging viruses, became the threats with which we are now faced.

Creating antibiotics is easy. This consists of finding the substance that kills the bacteria, or at least inhibits its growth (bacteriostasis). The antibiotic attacks the bacteria itself and even though they are 'prokaryotes', bacteriae are living organisms which can exist autonomously if they dispose of the necessary substrates. In real life nothing is, obviously, so simple, but the antibiotic saga was and remains an enormous success. We have been able to identify more than 10,000 antibiotic molecules. At least 400 led to further developments and more than 150 were commercialized. Each are efficient if the favorable pharmacodynamic and pharmacokinetic conditions are identified and present, and if certain important problems of tolerance and interaction have been solved. It should not be forgotten that the actions targeted on bacteriae are many and vary according to the antibiotics: inhibition of external membrane synthesis, of DNA, of RNA or mainly ribosome proteins.

A virus is a parasite that cannot exist outside the cells it will infect in order to reproduce, since it cannot do so on its own. A virus is not really a living organism. A single infected cell can produce, before dying at the end of its cycle, hundreds of copies of a virus. Contrary to an antibiotic which is a killer, an antivirus is only a mediator which will prevent the virus to either penetrate the cell or to leave it, or both. An antivirus is a molecule which disturbs the replication cycle of one or several viruses; it can slow down, but rarely stop, a viral infection. It does not eliminate viral particles, but rather interferes with one or several steps of viral replication. Antiviral chemotherapy has long experienced slow and difficult development, which is a consequence of a virus' intrinsic properties: strict intracellular parasitism, incapacity to self-replicate, diversity (variable size, simple or complex genome, ADN or RNA virus…). Since the very beginning, in 1960, the invention of antiviral medication has been difficult and has not had (at least under the same conditions) the same success as antibiotics.

Viral infections treated therapeutically can be acute (influenza, herpesviridae, coronavirus), latent with reactivation (herpes), or chronic (HIV, hepatitis B, hepatitis C). Antiviral medication will come up against two hurdles: interference J o u r n a l P r e -p r o o f with normal cellular metabolism and the virus' genetic variability (especially HIV). As was stated above, antivirals are virustatic (reversible inhibition of viral replication). Many are competitive inhibitors of RNA or DNA polymerases. They are prodrugs requiring a bi or tr-intracellular phosphorylation to be active. This is the case of antivirals for the herpes virus. Only the recent antivirals for chronic hepatitis C manage to completely eradicate the virus and thus cure the patient. These are called direct action antivirals, and are protease and polymerase inhibitors.

Also, corresponding pharmacological classes must be used with precaution due to their many undesirable side effects and medication interactions via the induction/inhibition of certain cytochromes.

For the public at large the discovery of a new medication is not difficult. All it requires is research, people, money and trying anything and everything knowing that something will work.

The problem lies in the fact that discovering antiviral medication is not simple at all. This is the lesson of history, but who is aware of it?

Yellow fever, Ebola, Lassa, Marburg, Hantavirus and other hemorrhagic fevers, rabies, and different encephalitis, plus illnesses which often make the news: dengue, Chikungunya, Zika, not to mention poliomyelitis and of course measles, rubella and the mumps. We can also name the many coronaviruses and HRSVs. This list is far from being exhaustive.

It is true that only one virus was eliminated from the face of the earth: smallpox, and vaccination is no longer required. This ancient epidemic was possibly the sixth plague of Egypt; and after 40 years we can now say that this was a great success. The WHO announced one month ago that wild strains of poliomyelitis in Africa were eradicated; although in reality we know (for several reasonsamong which is the diffusion of living virus vaccinations) that we are far from being able to suspend the vaccination for this disease which has disappeared from most countries.

There are also the complaints for which antiviral treatments were invented.

We will not describe here the virological reasons which make progress so painful. We will simply show a diagram noting target actions of influenza antivirals and highlighting the complexity of research: J o u r n a l P r e -p r o o f Schematic cycle of influenza virus multiplication and antiviral target actions [2] We are describing the antiviral history to show that nothing is simple.

There have, however, been fabulous successes.

The most impressive has been HIV treatment; it has been long but it is also an incredible part of the history of anti-retroviruses. The first product, AZT, zidovudine, was initially used in 1986, although its inefficiency was quickly recognized since it did nothing to alter the prognosis. Combination therapy was quickly looked into and began at the beginning of the 1990's with didanosine (Videx®) and stavudine (Zerit®). It was an improvement, but not much of one. Real progress came about with anti-proteases and subsequent classes (integrase, fusion and maturation inhibitors) and above all tri-therapy which came out at the beginning of 1996. For those who lived through that period the upheaval was dramatic: AIDS, the diagnosis of which once gave patients a life expectancy of no more than 2 years, became treatable. One quarter of a century later you can still meet people who were initially condemned to death and who came back to life. Patients no longer die of AIDS if they follow the treatment, although this comes at the price of a permanent, continuous, strict and expensive regimen. This was a revolution, but it took 15 years between the discovery of the virus and that of efficient treatments. Since 1996, great work has gone into finding more active, accessible and tolerated treatments. More than 50 anti-retroviruses have been developed. The dream remains to be able to stop all medication, but 40 years after the illness's first appearance, we still do not have a treatment which can definitively eradicate this virus.

Many medications are available for viral hepatitides, although it took two decades to establish optimal therapeutic strategies.

The treatment of hepatitis C has been transformed almost miraculously since 2014 -20 years after the discovery of HCVwhen so called direct-action antivirals were proposed. These cured 95% of chronic infections and are fixed associations of 2 or 3 protease and/or polymerase inhibitors.

They allow for treated patients to eliminate the virus and heal the infection.

The treatment of hepatitis B is more complicated. There are many treatments, such as interferon, nucleoside and nucleotide analogues, although these do not cure; they are used to attempt to stabilize fibrosis, prevent cirrhosis and hepatocellular carcinoma. Above all, there is a very efficient vaccination which should prevent future viral infection.

The best influenza treatment is vaccination. Influenza antivirals cannot be considered a total success, however. In 1967, amantadine received FDA approval in the United States for curative and preventive influenza treatment. Target viruses currently resist this treatment. When one examines this case, it can be clearly seen that no clinical efficiency has ever been demonstrated. One can only wonder why this product is still legally described, in 2020, as prophylaxis of influenza and respiratory infection due to influenza A virus. An FDA update never took place.

Neuraminidase inhibitors were developed in the 1990s. Initially zanamivir and then oseltamivir were marketed between 1999 and 2001. The debate on their efficiency has raged for a ¼ of a century and is still not settled. Oseltamivir is prescribed as a post-exposition prophylactic as well as an influenza treatment. Even if the level of efficiency proof is weak, it is strong enough to justify continued prescription of oseltamivir to patients at-risk of complications or to treat severe influenza (HCSP -French Supreme Council of Public Health, on 16 March 2018). It is quite probable that if oseltamivir is efficient, it could only be so when administered rapidly at the beginning of treatment and within 48 of initial symptoms. Oseltamivir has recently been severely criticized by the French Supreme Health Authority (HAS, on 24 June 2020) which may lead to recommendation modifications. The conclusions are:

As a prophylaxis, the Actual Benefit is weak during a declared or potential influenza pandemic; it is insufficient in other situations (prophylaxis during seasonal influenza epidemics).

during seasonal influenza epidemics).

As a cure, the Rendered Medical Service is insufficient to justify reimbursement by the French Social Security in the framework of curative influenza treatment in the case of seasonal influenza epidemic or influenza pandemic.

Without being able to conclude the debate on these antivirals, it can be said that their efficiency and utility are uncertain.

No truly active treatment against the influenza virus has been developed in the past 50 years.

Even if vaccination is not 100% efficient, it remains the most effective preventive tool to fight influenza and its associated complications, especially for at-risk subjects.

Ribavirin is different; it is older (1972); it is an analogue nucleoside used in default of other treatments for many severe viral infections: influenza, HRSV, measles as well as Lassa and Hantaan fevers even without patent proof of efficiency. Ribavirin is still recommended in association with other antivirals for treating chronic hepatitis C. It is probable that the direct action antivirals described above will lead to its disappearance.

There is no specific treatment for the EBV virus, be it infectious mononucleosis or other manifestationsessentially different lymphomas.

CMV is at the origin of highly varied pathologies among the immunocompetent, although especially among the immunodeficient. Antiviral treatments had greatly progressed before AIDS tritherapies were invented; CMV is one of the first opportunistic infectionswith its many clinical forms: retinitis, pneumopathies, digestive, hepatitis or neurological localizations…ganciclovir and its prodrug valganciclovir (a nucleoside analogue), foscarnet (pyrophosphate analogue), letermovir (direct action antiviral). Cidofovir was taken off the market 6 years ago (renal toxicity). During the AIDS epidemic, the main curative preventive treatment for CMV was to give patients back their normal immunity and in this framework these antivirals are no longer used. They remain very important, however, in the treatment and prevention of CMV infections coupled with diverse immunodeficiencies.

The invention of acyclovir at the end of the 1970s was a real revolution in the treatment of dramatic encephalitic herpes. Before this, the mortality rate was 80% and many survivors had aftereffects. Afterwards, mortality went down to between 20 and 10%, although aftereffects were noted in 40% of survivors. Treatment precocity as well as immediate care were major prognostic elements.

Acyclovir is a direct action antiviral. After having been phosphorylated in triphosphate acyclovir by a viral thymidine-kinase only present in virus-infected cells, it acts as a selective competitive inhibitor of the viral polymerase DNA. The incorporation of this nucleoside analogue stops the DNA chain's elongation, thus interrupting the synthesis of viral DNA. Viral replication is thus blocked.

This method can also be used against HSVs and VZVs.

Other herpes medications are: valacyclovir, which is merely an acyclovir prodrug and brings with it much improved bioavailability with oral administration. There is also famciclovir.

Other than encephalitic herpes (thankfully rare -2 cases/one million inhabitants), these antivirals are recommended for various frequent manifestations of herpes. They are well known and we will not describe them here. If required, the recommendations were listed in HAS 2006 as well as the product characteristics of each antiviral medication.

Acyclovir can be a preventive for reappearances of genital or cutaneous-mucosal herpes.

Intravenous acyclovir treatment is reserved for at-risk varicella patients: those with immunodeficiency, the new-born and pregnant women.

In case of shingles, acyclovir, valacyclovir and famciclovir are recommended in Product Characteristics, especially in cases of ophthalmic shingles. One requirement is to begin treatment as quickly as possible, within the first 72 hours. With those suffering from immunodeficiency in cases of generalized shingles, parenteral administration is necessary.

Even with 45 years hindsight, acyclovir was, and remains, a great leap forward in the treatment of HSV and VZV infections, especially in their acute and generalized forms and with immunodeficient patients.

Prevention of varicella by vaccination is recommended in a dozen precise situations in the vaccination schedule. Shingles prevention with the Zostavax® vaccine is possible and recommended for subjects 50 years and older.

As soon as this pandemic was identified, hundreds of research studies were launched to find THE ANTIVIRAL TREATMENT for SARS-Covid-2.

There were numerous possible targets as we can see in the diagram below:

Experimental treatment strategies attempt to interfere with different steps in the coronavirus replication cycle [3] .

The February 27 edition of the International Journal of Infectious Diseases mentioned 31 medicines which seem to be likely candidates for the prophylaxis and treatment of Covid-19 infections. All are existing medications, which have been proven safe for humans and which will therefore be, while awaiting new molecules, good treatment candidates for this disease.

Those mentioned are barcitinib, lopinavir, darunavir, favipiravir, remdesivir, ribavirin, galidesivir, chloroquine and many others including such antibiotics as teicoplanin, oritavancin, dalbavancin and azithromycin.

The objective of this article, however, is not to judge the history of the several hundred clinical trials which have taken place over the past 10 months.

Two got a lot of press: Chloroquine (or more exactly, hydroxychloroquine). Unless one is of consummate bad faith, no proof of efficiency exists.

Remdesivir, the history of which culminates in the French Transparency Commission (TC) opinion dated September 16, 2020, which included the following harsh words: This information does not allow us to draw conclusions with any certainty as to its efficiency, whether depending on the illness's progression or on the optimal length of treatment …This committee regrets this and is surprised that remdesivir's antiviral activity had not been evaluated in studies other than the Chinese study in which remdesivir's activity on viral loads was not proven.

The TC considers that the rendered medical service of remdesivir is:

-Weak in the treatment of patients suffering from pneumonia requiring low-dose oxygen therapy; -Insufficient in the treatment of patients suffering from pneumonia requiring high flow oxygen therapy or oxygen therapy during noninvasive or invasive assisted ventilation or ECMO.

The results of an initial Japanese favipiravir trial have just been announced (AFP). The reduction of a few days of evolution does not allow any conclusion to date greater than that of remdesivir.

The final verdict is not yet in, but as of September 23 we cannot claim this to be a clear victory.

We cannot end this discussion on the difficulties involved in inventing antiviral medication without mentioning that as of today we have 16 antiviral vaccinations. Fourteen are part of the vaccination schedule or are recommended for travel; two are being considered: one for dengue fever (Dengvaxia®) which is still problematic and one very recent vaccine for Ebola virus (Ervebo®) the future place of which we still ignore.

The SARS-CoV-2 vaccination will possibly be the answer to this infection. All we need is a tiny bit of a huge amount of patience.

Le naufrage des « essais cliniques » ! Ou comment les méfaits d'un virus ont pu mettre à mal la rigueur et compromettre la réponse à l'urgence. F

Race to find COVID-19 treatments accelerates

Mettre au point un antiviral : pas si simple ! F. TREMOLIERES Actualités Vidal